Compare IDEXX Laboratories, Inc. (IDXX) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Rockwell Automation — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while Rockwell Automation trades at $446.44 (market cap $49.64B). The key difference: IDEXX Laboratories, Inc. and Rockwell Automation are close in size by market cap, and Rockwell Automation pays a 1.23% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | ROK | |
|---|---|---|
Market Cap | $46.22B | $49.64B |
Sector | Health | Industrials |
52-Week High | $766.68 | $495.08 |
52-Week Low | $526.44 | $333.75 |
Enterprise Value | $47.12B | $52.77B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Rockwell Automation (ROK) trades at $451.86, up 3.82% over 24 hours, with a neutral technical signal. The stock exhibits strong fundamentals, including a 49.09% gross margin and consistent earnings beats, with Q2 2026 EPS of $3.49 surpassing the $3.38 estimate. Recent news highlights AI integration in quality management systems, signaling innovation momentum. Valuation ratios are elevated, with a P/E of 41.85 and P/S of 5.6, reflecting premium pricing.
The outlook remains positive due to robust earnings performance and raised fiscal 2026 guidance, though high valuation multiples and inflation pressures pose risks. Analyst consensus is a Buy with a $507 price target, suggesting 12% upside. Key risks include cost inflation and competitive threats in industrial automation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
